Internationally Renowned Lung Disease Expert Joins NDRI Board

PHILADELPHIA–()–Vera P. Krymskaya, PhD, MBA, FCPP, whose seminal discoveries at the
University of Pennsylvania Center for Pulmonary Biology paved the way
for an FDA-approved clinical treatment for the rare lung disease
lymphangioleiomyomatosis (LAM) and the inherited hamartoma syndrome,
tuberous sclerosis complex (TSC), was elected Feb. 2 to a three-year
term on the Board of Directors of the Philadelphia-based National
Disease Research Interchange (NDRI).

Dr. Krymskaya is a professor of medicine at the Perelman School of
Medicine and leads Penn’s Laboratory of Rare Lung Diseases in the
Pulmonary, Allergy & Critical Care Division of the Department of
Medicine. She specializes in rare and common lung diseases, including
LAM, TSC-LAM, Birt-Hogg-Dube, idiopathic multicentric Castleman’s
disease, pulmonary arterial hypertension, chronic obstructive pulmonary
disease and asthma.

LAM tissues procured by NDRI, in cooperation with the LAM Foundation,
helped Dr. Krymskaya uncover the function of tumor suppressor tuberous
sclerosis complex 2 (TSC2) that paved the way for the immunosuppressive
drug sirolimus (also known as rapamycin or Rapamune) — the first
effective treatment for LAM. Currently, she is principal investigator of
the SOS Clinical Trial to determine the safety of simvastatin, an
HMG-CoA reductase inhibitor or lipid-lowering medication, in combination
with either sirolimus or everolimus (also known as Afinitor) in patients
with LAM and TS-LAM.

“Dr. Krymskaya’s expertise in rare lung disease will be instrumental in
advancing NDRI’s contributions toward scientific research into rare and
common lung diseases, which impact so many people in the prime of their
life,” said Bill Leinweber, president and CEO of NDRI, the nation’s
leading source of human tissues, cells and organs for scientific
research. “Aligning ourselves with great biomedical minds offers
critical insight to the very specific needs of researchers whose work
toward critical breakthroughs promises to change the trajectory of care
for millions of individuals.”

Due to her groundbreaking research efforts, Dr. Krymskaya has received
numerous awards including the Science Advancement Award and Established
Investigator Award from the LAM Foundation, continued funding from
National Institutes of Health/National Heart Lung and Blood Institute,
Department of Defense, and American Lung Association. She serves on the
Scientific Advisory Board of the LAM Foundation, and the Castleman’s
Disease Collaborative Network. She is a member of the Department of
Defense TSC Research Program Scientific Peer Review Council, and serves
on the editorial board of the American Journal of Respiratory Cell and
Molecular Biology and as a reviewer for many reputed journals including
the Journal of Clinical Investigation, Cancer Research, and Proceedings
of the National Academy of Sciences, among others. Dr. Krymskaya is an
elected fellow of the College of Physicians of Philadelphia.

At the University of Pennsylvania, she is chair-elect of the Penn Forum
for Women Faculty, and a member of the Cardiovascular Institute, Center
of Excellence for Environmental Toxicology, LAM Clinic, and the Abramson
Cancer Center.

About NDRI

The National
Disease Research Interchange (NDRI)
is the nation’s leading source
of human tissues, cells and organs for scientific research. A
not-for-profit 501 (c)(3) organization founded in 1980, NDRI is funded
in part by the National Institutes of Health, public and private
foundations and organizations, pharmaceutical and biotechnology
corporations. NDRI is a 24/7 operation that partners with a nationwide
network of over 130 tissue source sites (TSS), including organ
procurement organizations (OPO), tissue banks, eye banks, and hospitals.
The TSS, are distributed throughout the USA, in 45 states, with
concentrations in major metropolitan areas on both the east and west
coasts. Their wide geographic distribution allows NDRI to provide
biospecimens from donor populations with diverse demographics and also
facilitates the timely and efficient provision of fresh tissues directly
to researchers around the world. By serving as the liaison between
procurement sources and the research community, NDRI is uniquely
positioned to support breakthrough advances and discoveries that can
affect advances in the treatment and cure of human diseases.

Source link

more recommended stories

Social Media Auto Publish Powered By :
%d bloggers like this: